Skip to content

Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia

Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02141737
Enrollment
272
Registered
2014-05-19
Start date
2014-05-31
Completion date
2014-10-31
Last updated
2014-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Brief summary

To evaluate the effect of pre-injection of lidocaine on myoclonus induced by induction with etomidate during general anesthesia in elderly patients

Interventions

Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.

1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.

DRUGnormal saline

2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.

DRUGMidazolam Injection

0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.

3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.

0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.

Sponsors

Tang-Du Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to 81 Years
Healthy volunteers
No

Inclusion criteria

* 1\. Aged between 60 and 81 years 2. Body mass index: 20 to 30 kg/m2 3. American Society of Anesthesiology (ASA) Physical Status: Ⅰ or Ⅱ 4. Signed informed consent form

Exclusion criteria

* 1\. Use of sedatives or opioids 2. History of central nervous system diseases, like epilepsy, shaking palsy, or chorea, etc 3. Hyperthyroidism 4. Serious diabetes 5. Hyperkalemia 6. Cardiac surgery 7. Serious ventricular disease or atrioventricular block 8. Liver or renal dysfunction 9. Allergies to amide local anesthetics or fat emulsion

Design outcomes

Primary

MeasureTime frameDescription
severity of myoclonus induced by90 seconds from the beginning of etomidate injectionmyoclonic movements are graded as 0=no myoclonus, 1=mild myoclonus (short movement of a body segment e.g., a finger or a wrist), 2=moderate myoclonus (mild movement of two different muscle groups e.g., face and arm), or 3=severe myoclonus (intense myoclonic movement in two or more muscle groups, fast adduction of a limb)
intensity of injection painduring the injection of etomidate, expected to be within 1 minutesThe intensity of pain was graded using a verbal rating scale. 0-None (negative response to questioning) 1. Mild pain (pain reported only in response to questioning without any behavioral signs) 2. Moderate pain (pain reported in response to questioning and accompanied by a behavioral sign or pain reported spontaneously without questioning) 3. Severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawl or tears)

Secondary

MeasureTime frameDescription
hemodynamic parameters after injection of etomidatebaseline to 2 minutes after injetion of etomidateHeart rate and mean arterial pressure will be recorded before induction, before the injection of etomidate, 1 minute and 2 minutes after injection of etomidate

Countries

China

Contacts

Primary ContactYu Guo
guoyu986121@163.com+86-18009200936

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026